Prespecified secondary pooled analysis of 3 finerenone trials (18,991 participants, 35% women): women had similar adjusted risk of HF hospitalisation or CV death as men (HR 0.97) but lower all-cause mortality (HR 0.83); finerenone's benefit did not differ by sex.
Secondary analysisn = 18,991
Pabon et al. Sex differences in cardiovascular-kidney-metabolic syndrome: the FINE-HEART pooled analysis